{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:17:59Z","timestamp":1787807879096,"version":"build-2784847793"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jconrel.2026.115167","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:42:38Z","timestamp":1783600958000},"page":"115167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Application of a glyceride-mimetic prodrug strategy to deliver protease inhibitors to gut lymph to alleviate organ failure"],"prefix":"10.1016","volume":"397","author":[{"given":"Yining","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeevini","family":"Babu Reddiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.H.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"Trevaskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2026.115167_bb0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1053\/j.gastro.2010.06.010","article-title":"Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis","volume":"139","author":"Petrov","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115167_bb0010","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2004.039883","article-title":"Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis","volume":"53","author":"Johnson","year":"2004","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115167_bb0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamasurg.2022.0654","article-title":"The gut-lymph model gives new treatment strategies for organ failure","volume":"157","author":"Windsor","year":"2022","journal-title":"JAMA Surg."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115167_bb0020","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3748\/wjg.v23.i12.2106","article-title":"Regulation of intestinal permeability: the role of proteases","volume":"23","author":"Van Spaendonk","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115167_bb0025","doi-asserted-by":"crossref","first-page":"G969","DOI":"10.1152\/ajpgi.00290.2012","article-title":"Role of lipase-generated free fatty acids in converting mesenteric lymph from a noncytotoxic to a cytotoxic fluid","volume":"303","author":"Qin","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115167_bb0030","first-page":"374","article-title":"Mesenteric lymph: the bridge to future management of critical illness","volume":"8","author":"Fanous","year":"2007","journal-title":"JOP"},{"key":"10.1016\/j.jconrel.2026.115167_bb0035","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1097\/CM9.0000000000000928","article-title":"Gut-lymph-lung pathway mediates sepsis-induced acute lung injury","volume":"133","author":"Can","year":"2020","journal-title":"Chin. Med. J."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115167_bb0040","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.shk.0000048899.46342.f6","article-title":"Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury","volume":"19","author":"Deitch","year":"2003","journal-title":"Shock"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115167_bb0045","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.sla.0000143809.44221.9b","article-title":"Pancreatic duct ligation reduces lung injury following trauma and hemorrhagic shock","volume":"240","author":"Cohen","year":"2004","journal-title":"Ann. Surg."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115167_bb0050","first-page":"130","article-title":"The proteome of mesenteric lymph during acute pancreatitis and implications for treatment","volume":"10","author":"Mittal","year":"2009","journal-title":"JOP"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115167_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1172\/JCI130172","article-title":"Trypsin activity governs increased susceptibility to pancreatitis in mice expressing human PRSS1R122H","volume":"130","author":"Gui","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115167_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092357","article-title":"Safety evaluation and population pharmacokinetics of Camostat mesylate and its major metabolites using a phase I study","volume":"15","author":"Kim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115167_bb0065","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02167-21","article-title":"Semi-mechanistic pharmacokinetic-pharmacodynamic model of Camostat mesylate-predicted efficacy against SARS-CoV-2 in COVID-19","volume":"10","author":"Kosinsky","year":"2022","journal-title":"Microbiol. Spectrum"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115167_bb0070","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/cts.13052","article-title":"A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19","volume":"14","author":"Kitagawa","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115167_bb0075","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","article-title":"Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update","volume":"60","author":"Trevaskis","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115167_bb0080","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1124\/pharmrev.123.001159","article-title":"Intestinal lymphatic biology, drug delivery, and therapeutics: current status and future directions","volume":"76","author":"Reddiar","year":"2024","journal-title":"Pharmacol. Rev."},{"issue":"10\u221211","key":"10.1016\/j.jconrel.2026.115167_bb0085","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.addr.2011.05.019","article-title":"Intestinal lymphatic transport for drug delivery","volume":"63","author":"Yanez","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.115167_bb0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(86)90027-X","article-title":"Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules","volume":"34","author":"Charman","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115167_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2013.12.031","article-title":"Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies","volume":"177","author":"Han","year":"2014","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115167_bb0100","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.molpharmaceut.4c01272","article-title":"Optimizing triglyceride prodrugs of a model immunomodulator: conjugation through the phenol of mycophenolic acid (MPA) markedly promotes lymphatic drug transport","volume":"22","author":"Hu","year":"2025","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115167_bb0105","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s11095-014-1579-9","article-title":"Profiling the role of deacylation-reacylation in the lymphatic transport of a triglyceride-mimetic prodrug","volume":"32","author":"Han","year":"2015","journal-title":"Pharm. Res."},{"issue":"44","key":"10.1016\/j.jconrel.2026.115167_bb0110","doi-asserted-by":"crossref","first-page":"13700","DOI":"10.1002\/anie.201604207","article-title":"Glyceride-mimetic prodrugs incorporating self-immolative spacers promote lymphatic transport, avoid first-pass metabolism, and enhance oral bioavailability","volume":"55","author":"Hu","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"21","key":"10.1016\/j.jconrel.2026.115167_bb0115","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.lfs.2007.02.044","article-title":"The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents","volume":"80","author":"Ishikura","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2026.115167_bb0120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000199627","article-title":"Pancreatic and biliary excretion of camostat in dogs","author":"Kitagawa","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.jconrel.2026.115167_bb0125","article-title":"Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport","volume":"13","author":"Quach","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115167_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/catal14110787","article-title":"Advancements in serine protease inhibitors: from mechanistic insights to clinical applications","volume":"14","author":"Wei","year":"2024","journal-title":"Catalysts"},{"key":"10.1016\/j.jconrel.2026.115167_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120247","article-title":"Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat","volume":"596","author":"Lee","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115167_bb0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00011-012-0462-6","article-title":"Evaluation of N-acetylcysteine treatment in acute pancreatitis-induced lung injury","volume":"61","author":"Yubero","year":"2012","journal-title":"Inflamm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115167_bb0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365528009181493","article-title":"Experimental pancreatitis in the rat","volume":"15","author":"Aho","year":"2010","journal-title":"Scand. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115167_bb0150","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species difference of esterase expression and hydrolase activity in plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115167_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189837","article-title":"Sex-specific reference intervals of hematologic and biochemical analytes in Sprague-Dawley rats using the nonparametric rank percentile method","volume":"12","author":"He","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115167_bb0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.etp.2005.10.002","article-title":"Clinical chemistry and haematology historical data in control Sprague-Dawley rats from pre-clinical toxicity studies","volume":"57","author":"Petterino","year":"2006","journal-title":"Exp. Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115167_bb0165","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MPA.0000000000000775","article-title":"Continuous regional arterial infusion of protease inhibitors has no efficacy in the treatment of severe acute pancreatitis: a retrospective Multicenter cohort study","volume":"46","author":"Horibe","year":"2017","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115167_bb0170","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14740338.2021.1933942","article-title":"Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data","volume":"20","author":"Qin","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jconrel.2026.115167_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-230X-14-102","article-title":"Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis","volume":"14","author":"Seta","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115167_bb0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcrc.2018.01.021","article-title":"Role of Ulinastatin, a trypsin inhibitor, in severe acute pancreatitis in critical care setting: a retrospective analysis","volume":"45","author":"Lagoo","year":"2018","journal-title":"J. Crit. Care"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115167_bb0185","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00535-019-01644-z","article-title":"Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial","volume":"55","author":"Hirota","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115167_bb0190","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/MPA.0b013e31826495a0","article-title":"Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: a propensity score analysis using a nationwide administrative database","volume":"42","author":"Yasunaga","year":"2013","journal-title":"Pancreas"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115167_bb0195","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/jps.21659","article-title":"Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution","volume":"98","author":"Mohsin","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115167_bb0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2013.03.054","article-title":"Lipid-based formulations for oral administration of poorly water-soluble drugs","volume":"453","author":"Mu","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2026.115167_bb0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1081\/RRS-100107429","article-title":"Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs","volume":"21","author":"Porter","year":"2001","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2026.115167_bb0210","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0928-0987(00)00167-6","article-title":"Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and \u2018self-microemulsifying\u2019 drug delivery systems","volume":"11","author":"Pouton","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115167_bb0215","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12664-016-0647-y","article-title":"Pathophysiological mechanisms in acute pancreatitis: current understanding","volume":"35","author":"Singh","year":"2016","journal-title":"Indian J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115167_bb0220","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bcpt.13533","article-title":"Camostat mesylate against SARS-CoV-2 and COVID-19-rationale, dosing and safety","volume":"128","author":"Breining","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2026.115167_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100849","article-title":"Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial","volume":"35","author":"Gunst","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115167_bb0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/labinvest.3700203","article-title":"Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity","volume":"85","author":"Gibo","year":"2005","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jconrel.2026.115167_bb0235","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12053","article-title":"Camostat mesilate inhibits pro-inflammatory cytokine secretion and improves cell viability by regulating MFGE8 and HMGN1 in lipopolysaccharide-stimulated DF-1 chicken embryo fibroblasts","volume":"9","author":"Yuan","year":"2021","journal-title":"PeerJ"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:22:06Z","timestamp":1787804526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"alternative-id":["S0168365926005705"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115167","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of a glyceride-mimetic prodrug strategy to deliver protease inhibitors to gut lymph to alleviate organ failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115167"}}